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ABSTRACT

OIL/WATER NANOEMULSION BIODISTRIBUTION IN MICE UPON
INTRAVENOUS ADMINISTRATION
Jiayi Chen

The present study aimed to explore the biodistribution of O/W nanoemulsions
(NE) upon intravenous administration. Three NEs were prepared with distinctive droplet
sizes: SE (29 ± 1 nm), ME (214 ± 2 nm) and LE (883 ± 16 nm) without overlapping of
the size distribution. Kolliphor® HS15 was used as the only surfactant for these three
NEs, so that their droplets had similar surface structure. The NEs droplet size was stable
under room temperature for minimum 3 days in phosphate buffer saline (PBS) and in
mice plasma in vitro for 4-hour at 37°C. A lipophilic fluorescent dye, 1, 1’-dioctadecyl-3,
3, 3’, 3’-tetramethylindocarbocyanine perchlorate (DiI) was selected as the probe and
loaded in the SE, ME and LE (designated thereafter as DSE, DME and DLE,
respectively). A fluorometry for DiI was established with a linear range of 1.0-1000
ng/mL.
The processing procedure and assay method for biological samples were developed. DiI
extraction efficiency was 74.6-93.4%, depending on the tissues. For the biodistribution
study, tumor-bearing mice received intravenous injection of DiI (2-5 mg/kg) in free
solution (DS) or in the NEs via tail vein. The mice were sacrificed at sampling time
points and the biological samples were assayed for DiI concentrations. DS manifested
early tissues peak concentration (apparent Tmaxs at 0.5 h) followed by rapid decline, with

tissue recovery mainly from the liver, spleen and lungs. DSE had a comparable plasma
profile as DS but lower concentrations in the spleen and lungs as compared to the
corresponding tissue profiles followed by the administration of DS. DME showed a
sustained plasma circulation and a long-term non-specific higher tissue uptake with
significant accumulation in the heart, lung, liver and spleen. DLE displayed a favorable
accumulation in the RES organs including the lung, spleen, and liver. In conclusion, the
present study demonstrates that O/W NE exhibits altered biodistribution upon
intravenous administration. And these features may be utilized as a targeted drug delivery
and drug redisposition strategy.
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Chapter 1. Introduction

In this chapter, the following topics are elaborated:
•

How the research idea was formed

•

The literature search and the refinement of the research goals

•

The hypothesis, objective and specific aims

1.1. The formation of the research idea
Since the emerge of nanotechnology, many scientific areas have benefited significantly from its
introduction and revolution. For the field of biomedicine and pharmaceutical sciences, though
mentions of nanoparticles could be traced back as early as late 1970s, the term nanomedicine
appeared much later at the turn of last century (Astruc, 2015). It was even later in 2005 when the
term was first clearly defined by the European Science Foundation as “Nanomedicine uses nanosized tools for the diagnosis, prevention and treatment of disease and to gain increased
understanding of the complex underlying patho-physiology of disease. The ultimate goal is to
improve quality of life.” (European Science Foundation, 2005) The applications of
nanotechnology were further categorized into three areas of diagnosis, imaging agents and drug
delivery with nanoparticles (NP) in the size range of 1-1000 nm (Peer et al, 2007). Despite the
relative short history of biomedical applications of the technology, the growth of academic and
clinical research interest in nanomedicine has been explosively blossoming, resulted in tens of
thousands publications per year over the last decade. Nanomedicine holds such an enormous
promise for healthcare that in the United States, the National Institutes of Health (NIH) has
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continuously increased their annual funding to Research Project Grant Program (R01) focused on
nanomedicine ever since 2009, with more than $130 million invested in 2018 alone. It also
fostered several special initiatives/programs such as the National Cancer Institute (NCI) to
facilitate clinical translation of nanomedicines (He et al., 2019).
However, regardless of the tremendous investments and efforts spent, accumulatively there were
only 50 approved nanodrug products by the FDA as of year 2017 (Ventola, et al., 2017), among
which polymeric, liposomal and nanocrystal formulations were heavily represented. The extreme
high attrition rate for nanodrugs was attributed to multiple folds of reasons, of which the hardness
of characterizations, insignificantly improved efficacy, safety issues, complexity in
manufacturing, cost-benefit considerations, etc. all pose barriers to the survival of nanodrugs
against their conventional competitors (Kola and Landis, 2004).
In such context, a nanoplatform would be highly desired if it could address some of the
aforementioned obstacles. Indeed, a relative new nano-sized formulation strategy: nanoemulsion
(NE), has attracted more and more research interest. NEs are oil-in-water (O/W) or water-in-oil
(W/O) dispersion of two immiscible liquids stabilized by an appropriate surfactant with or
without other excipients. It is sometimes used interchangeably with submicron emulsion or mini
emulsion to distinguish from coarse/macro emulsions which have larger droplet sizes over 1
micron, yet on the other hand differentiate from microemulsions which differ tremendously in
structural aspects and long term thermodynamic stability (McClements, 2012; Singh et al., 2017).
NE provides a wide spectrum of formulation advantages such as the enhancement of lipophilic
drug payload and oral bioavailability, ease of preparation and scale-up, exclusiveness of organic
solvents and use of Generally Recognized as Safe (GRAS) materials, etc. Extensive researches
have been conducted to exploit NE by various delivery routes including oral (Soliman et al.,
2016), parenteral (Venkateshwarlu et al., 2010), topical (Hagigit et al., 2010) and intranasal
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(Shobhit et al., 2016). Currently, a few NE drug products have been approved by the FDA (Ganta
et al., 2014) while numerous are still undergoing clinical trials (Singh et al., 2017).
Quoted from Rivera, a nanomaterial should possess properties which neither the bulk material nor
the atoms or molecules of that same material display. Essentially, nanodrugs are
“pharmaceuticals engineered on the nanoscale, i.e., pharmaceuticals where the nanomaterial
plays the pivotal therapeutic role or adds additional functionality to the previous compound”.
(Rivera et al., 2010) In this sense, as a nanomaterial, NE could possibly alter drug
pharmacokinetics (PK) profile and/or redisposition in the organ/tissue as compared to the
corresponding free drug solution after intravenous (i.v.) administration.
Indeed, our interest on the potential of NE to alter PK and biodistribution was inspired by two
cases, the first one being the success of the well-known nanodrug product Doxil® (Doxorubicin
Hydrochloride liposome injection). Doxorubicin has been an anthracycline drug effective for a
variety of cancers but its cardiotoxicity had held back its use (Alexander et al., 1979). By loading
the drug into liposomes, Doxil® significantly reduced Doxorubicin cardiotoxicity by the
elimination of the intensive peak concentration in the heart, which eventually granted its approval
by the FDA (Papahadjopoulos et al., 1991). In fact, many nanodrug products gained approval not
by the enhancement of drug efficacy, but because of the reduction of drug or excipients related
side effects of conventional formulations. The second case is the discovery of the enhanced
permeability and retention effect (EPR), of which the centric principle was based on
molecule/particle size. Briefly, Yasuhiro Matsumura and Hiroshi Maeda found that radioactive
protein with molecular weight (MW) over 65,000 preferably accumulated in tumor tissues
compared with protein with MW 12,000 after intravenous injection to tumor bearing mice
(Matsumura and Maeda, 1986). This phenomenon, due to the unique tumor physiological
properties: hyper-vasculature, enhanced vascular permeability and little recovery of the
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macromolecules via the blood vessels and lymphatic system, was subsequently utilized as the
tumor passive targeting strategy (Maeda et al., 2013) and has been guiding the development of
nanoparticulate drug delivery system (DDS) ever since, though it has become controversial more
recently (Prabhakar et al., 2013; Nicholas and Bae, 2014).
Therefore, it would be meaningful to investigate whether NE could alter encapsulated drug
substances’ PK and biodistribution, and whether the NE droplet size played a role in such change.
A direct way to address the problem is to administer NEs with different droplet size intravenously
to investigate the biodistribution. Should the assumption be true, it could be utilized as a targeted
drug delivery and drug redisposition strategy to increase efficacy and/or to reduce off-target
organs toxicities. These potential benefits set up the premise for the current study.

1.2. The literature search and the refinement of the research goals
When we dig into the literature, we found numerous size-dependent biodistribution studies such
as polymeric NP (He et al., 2010), gold NP (Perrault et al., 2009), liposome (Liu et al., 1992) and
quantum dot (Popović et al., 2010), etc. The results from other nano DDS have confirmed that the
particle size is one of the major factors which governed the nanomaterials in vivo biodistribution.
Surprisingly, despite the recent blossoming research interests on NEs, studies of NE
biodistribution were quite scattered and for those focusing on the droplet size effect were further
limited.
One of the studies on NE droplet size effect on biodistribution was conducted by Attia et al.
(Attia et al., 2015). In their work, NE with mean droplet size of 55 and 100 nm were prepared by
use of the same lipid and surfactant at different percentage composition. Their findings suggested
that 55 nm NE was less uptaken by hepatocytes and macrophages in vitro, and less toxic to the
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mice in vivo which was demonstrated by the longer survival time after intravenous
administration. The authors attributed this decreased in vivo toxicity to the reduced cellular
uptake. Notably, no size-dependent impact of NE on biodistributions was observed based on the
plasma, liver, spleen and kidneys profiles. Nevertheless, this conclusion was questionable
because the two NEs size distributions significantly overlapped with each other, which very likely
caused the similar in vivo tissue profiles.
Another study by Chen and coworkers (Chen et al., 2016) used iodinated NEs with 25, 60 and
100 nm droplet size to investigate the size-dependent NE biodistribution. Similar cellular uptake
results were observed that increased size caused increased phagocytic uptake. The in vivo
computed tomography (CT) results after intravenous administration of NEs demonstrated
enhanced liver and spleen accumulation as the increase of the size.
Based on what have been reported in the literature, we speculated that NE droplet size should
have impact on their in vivo biodistributions like the other nanomaterials. However, this effect has
not been clearly elucidated because of two reasons. First, the mean droplet size of the NEs studied
were selected too close which posed the argument that the similar biodistribution could be due to
the essentially no-significantly-different sizes in the in vivo environment. Secondly, the droplet
size studied were no more than 100 nm which left the vacuum of the knowledge about the bigger
size. Besides the liver and spleen, the lungs are also main constitution of the reticuloendothelial
system (RES) in the body which is responsible to uptake particulate matters (Saba, 1970).
Therefore, larger nanoparticles could also see preferable dispositions in the lungs (Blanco et al.,
2016). To more clearly address the problem, an extended span of NE droplet size became
necessary. Hence, a reasonable approach is to develop NEs with droplet size towards the two-end
of the submicron range, i.e., less than 50 nm and close to 1 micron, and an intermediate size in
between. However, unlike solid nanoparticles, the liquid droplets usually present much less
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precise sizes, and this phenomenon would be further magnified as the mean droplet size of NE
increases. According to our preliminary data, the mean droplet size of a certain NE did not
necessarily correlate with its actual size distribution, usually due to multi-modal distribution or a
wide unimodal distribution. In addition, the increased size also deteriorated the stability of NEs
significantly. All these factors could probably explain the remarkable limitations of the previous
studies on the size effect of NEs as compared to the studies on the size effect of solid
nanoparticles.
To put in short, the present research goal was refined as to focus on the development of more
defined droplet size NEs with narrow size distribution which significantly differs from each other
in the sub-micron range, and to investigate the droplet size impact on their in vivo
biodistributions.

1.3. The hypothesis, objective and specific aims
Our hypothesis was that O/W NEs could alter encapsulated drug biodistribution and such
alteration was impacted mainly by the droplet size of the NEs.
To test the hypothesis, the overall objective of the study was to develop O/W NEs with
significantly different droplet size and similar droplet surface structure, and to compare their in
vivo biodistributions. The specific aims of the study were as follows:
1. To prepare O/W NEs which have distinct size (<50 nm for the small-size NE (SE), ~200
nm for the medium-size NE (ME) and ~1 micron for the large-size NE (LE)) with narrow
size distribution.
2. To evaluate the prepared NEs stability for their suitability for the in vivo study.
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3. To identify an agent to label the NEs.
4. To validate the assay method for the labeling agent.
5. To establish a tumor-bearing animal model for the in vivo study.
6. To establish the in vivo biological sample preparation and assay protocol.
7. To study and compare the biodistribution of labeled NEs with distinct droplet sizes after
intravenous administration.
Specific Aims 1-2 regarding the preparations and characterizations of the NEs are addressed in
Chapter 2. Specific Aims 3-6 are addressed in Chapter 3, and Specific Aim 7 of the in vivo
assessments is elaborated in Chapter 4. Finally, in Chapter 5 the entire study is summarized
together with a few insights and discussions.
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Chapter 2. Preparation and evaluation of nanoemulsions with
distinct droplet sizes

In this chapter, the following topics are addressed:
•

The preparation of O/W NEs with distinct droplet size and narrow size distribution

•

The stability of the prepared NEs under certain conditions

2.1. Introduction
The preparation methods for NE can be categorized into high-energy method, low-energy
method, and a combination of the two (Mason et al., 2006). Low-energy method usually produces
ultra-fine droplets, and it is generally limited by oil type and emulsifiers that can be used. It can
be further classified as spontaneous emulsification (Bouchemal et al., 2004) and phase inversion
(Fernandez et al., 2004). High energy method, on the other hand, depends on mechanical devices
to create disruptive forces for size reduction, which is usually implemented by ultra-sonicators,
high pressure homogenizers or microfluidizers. This method is more versatile in which almost
any kinds of oils and emulsifiers can be subjected to nano-emulsification. However, the major
limitation lies in the instrumental cost and the generation of high operational temperatures which
rules out thermolabile drugs (Singh et al., 2017).
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2.2. Preparation of O/W NEs with distinct droplet size
2.2.1. Materials and methodology
Captex® 8000 (C8 triglyceride), Captex® 1000 (C10 triglyceride), Capmul® MCM NF (C8/C10
monoglyceride) were kind gifts from Abitec Corporation (Abitec, WI). LabrafacTM Lipophille
WL1349 was a kind gift from Gattefosse Corporation (Gattefosse, NJ). Kolliphor® RH 40,
Kolliphor® HS 15, Tween® 80 were purchased from Sigma-Aldrich (St. Louis, MO). Soybean
oil (Spectrum, NJ), Pluronic F68 (BASF, NJ) and soybean lecithin (Alfa Aesar, MA) were
purchased through VWR.
To prepare the NEs with desired droplet size and size distribution, commonly used medium chain
mono-/di- and triglycerides, long chain triglycerides and commercially available surfactants were
screened with an emphasis on GRAS ingredients. For the SE, low energy preparation method was
applied. Briefly, predetermined amount of lipid(s) and surfactant were mixed at 50°C, 300 rpm
for 2 h to ensure homogeneous preconcentrate (MaxQ 4000, Thermo Fisher Scientific, MA). The
preconcentrate was cooled down to 37°C prior to be mixed with 37°C distilled water (1:4 w/v).
The SE was obtained by gently shaking the mixture.
For the ME and LE, high energy preparation method was utilized. The preparation procedures
included homogenization and/or ultrasonication individually or in combination. Processing
parameters such as homogenization speed (5000, 10,000 and 20,000 rpm) and time (2, 5 and 10
min), and ultrasonication amplitude (20, 30 and 40%), on-duty/rest cycle pattern and on-duty
duration (2 to 6 min) were evaluated. Lipid(s), surfactant, and distilled water were first weighed
and homogenized at 30 °C with various speed and time to produce coarse emulsion (VirTis
Tempest I.Q.2, SP Scientific, PA). The coarse emulsion was subsequently ultrasonicated at
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various amplitude for different period of on-duty time, with a 10 s/10 s on-duty/rest cycle. Ice
bath was applied to prevent excessive heat generated during the process (Cole Parmer, IL).
The prepared NEs were properly diluted before droplet size and polydispersity index (PI)
determination by dynamic light scattering (DLS, Zetasizer Nano ZS, Malvern, U.K.).

2.2.2. Results and discussions
A variety of commercially available lipids (medium chain mono/di-glyceride, medium chain
triglyceride and long chain triglycerides), surfactants (Polysorbate 80, Poloxamer 188, Polyoxyl
(40)-hydrogenated castor oil, Polyethylene glycol (15)-hydroxystearate and soybean lecithin)
were screened individually or in combinations. The criteria for the screening included: (1) The
capability to produce desired NEs droplet size with narrow distribution; (2) The formulation
should be able to solubilize the labeling agent at relevant dose for in vivo application; (3) The
surface of the droplets should be similar across different NEs as best; (4) The NEs need to have
suitable stability for in vivo assessment; (5) If possible, the ingredients should be approved by
FDA for parenteral use or GRAS ingredients and (6) Formulations and preparation should be
simple if possible.
Intralipid® was invented by the Swedish physician and nutrition researcher Arvid Wretlind,
(Isaksson, et al., 2002). The product gained approval by the Food and Drug Administration
(FDA) in 1972 and has been the standard intravenous lipid nutrition medication in the United
States to the present. It is comprised of GRAS ingredients, i.e., soybean oil (20%) and egg
lecithin (1.2% w/v), with the latter one exhibiting good emulsifying and O/W interface stabilizing
effect (Hammond et al., 2005). Besides, the label specifies the mean droplet size of the product of
0.5 micron (Intralipid® 20% I.V. fat emulsion FDA label). All these features made the well-
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established Intralipid 20% a reasonable starting point, and the composition of soybean oil and
soybean lecithin along with the preparation parameters were adjusted to achieve desired NE
droplet sizes. Nevertheless, NEs associated with soy lecithin usually exhibited wide span of size
distribution (100 nm to 1 micron) and sometimes produced multimodal rather than monomodal
size distribution. The droplet size was neither resistant to the dilution. For example, despite the
label claiming a 0.5 micron in size for Intralipid 20%, about 300 nm was observed upon dilution
in distilled water through 5- to 500-fold. Furthermore, as a long chain triglyceride, soybean oil
may not be the best lipid to solubilize lipophilic drugs as compared to medium chain glycerides
(Hippalgaonkar et al., 2010). Subsequently, medium chain mono/di- and triglycerides were tested
with some synthetic surfactants, with the centric emphasis being the distribution of the NEs size.
As illustrated in Figure 2.1, both NEs exhibited similar mean sizes, but none of them could be
further considered as they either presented a multi-modal or a wide unimodal distribution.
Thereby, rather than simply report the mean droplet size, the individual distribution pattern would
actually make more sense in the current study and should be presented instead. However, due to
the limited space, the results are summarized in Table 2.1 in the manner of the range of droplet
size and polydispersity index (PI) by the mainly tested ingredients and preparation parameters.
Kolliphor® HS15 (HS, formerly under the name Solutol® HS 15) is a non-ionic surfactant which
is frequently used in in vitro screening and in vivo efficacy studies of poorly soluble new
chemical entities (NCE) (Shah et al., 2014). It is synthesized by reacting 12-hydroxystearic acid
with ethylene oxide in presence of an alkaline catalyst to yield the major components,
polyethoxylated derivatives (~70%) and the minor components (free polyethylene glycol [PEG],
~30%). HS provides profound safety and toxicological profile relatively better than polysorbate
80 and Kolliphor® EL (Wang et al., 2004), which makes it an excellent choice for screening and
pre-clinical pharmacokinetic (PK) studies of cytotoxic and oncology drugs among many other
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indications (Ali and Kolter, 2019). Furthermore, it is also approved by FDA in injectable and
ophthalmic drugs. Besides these unique advantages, more importantly though, when combined
with the medium chain triglyceride LabrafacTM Lipophille WL1349 (WL) at various percentage,
it produced desired NE droplet size distributions and thus both of them were selected as the final
ingredients (Table 2.2).
The NEs compositions and preparation methods are summarized in Table 2.3. Briefly, for ME
and LE preparation, a process of homogenization at 10,000 rpm for 10 min yielded coarse
emulsions of large droplet sizes with multiple peaks. The coarse emulsions had extremely limited
stabilities that they tended to be phase separated in as short as 15 min. Hence, a subsequent step
of ultrasonication was applied to reduce the droplet size and to improve uniformity and stability
as well. As the length of on-duty time and the energy input affected the NE droplet size (Delmas
et al., 2011), both parameters were evaluated (2, 4 and 6 min for the on-duty time whilst 20, 30
and 40% amplitude for the energy input). The on-duty run for 6 min with 10s/10s cycle at 20%
amplitude produced the most uniform NEs of the desired droplet sizes. For SE, Capmul® MCM
NF (MCM) was also included to further reduce the droplet size. Figure 2.2 depicts the merged
peaks distribution for one set of SE, ME and LE. They had droplet size distribution of 30 ± 9 nm
for SE, 212 ± 64 nm for ME and 893 ± 158 nm for LE, respectively. Table 2.4 summarizes the
droplet size and PI for the triplicate. They had unique droplet distribution which did not overlap
with each other. This was of significance because it excluded the potential interferences of the
effect from a “mixed” droplet and made it clear to interpret the further in vivo data. In addition,
since the major surfactant was constant (HS), the effect of surface charge and chain length could
also be minimized. (Buszello et al., 2000; Pozzi et al., 2014)
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Figure 2.1 The illustration of two NEs with closed mean droplet size yet distinct size
distribution pattern.
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Table 2.1 The major screened ingredients, processing parameters, and droplet size
and polydispersity index range
Lipid/

Homogenization

Ultrasonication

Droplet size

Surfactant

(rpm, time, temperature)

(Time,

(nm)

PI

Amplitude)
Intralipid 20%

N/A

N/A

243 – 266

0.08 – 0.15

SO (10-20%) / SL (1.2%)

N/A

5 min, 40%

162 – 170

0.18 – 0.26

SO (20%) / SL (1.2%)

275 rpm, 2 h, 45°C

20 s-5 min, 40-

185 – 368

0.17 – 0.54

70%
SO (1-30%) / SL (1.2%)

15,000 rpm, 10 min, 30°C

4 min, 25%

144 – 455

0.20 – 0.27

SO (20-80%) / RH (20-80%)

275 rpm, 2 h, 45°C

N/A

25 – 734

0.06 – 0.65

SO (5-20%) / Tween80 (1%)

15,000 rpm, 10 min, 30°C

2-4 min, 25%

198 – 724

0.17 – 0.29

SO (20%) / TW (1%)

10,000 rpm, 10 min, 30°C

1-8 min, 20%

353 – 472

0.01 – 0.27

SO (50%) / TW (0.25%)

10,000 rpm, 10 min, 30°C

4-8 min, 20%

1384 – 1473

0.05 – 0.43

SO (20-30%) / HS (20-30%)

15,000 rpm, 5 min, 30°C

4 min, 25%

91 – 175

0.02 – 0.40

MCM (0.25-20%) / F68 (2%)

275 rpm, 2 h, 45°C

80 s, 40%

129 – 337

0.27 – 0.58

MCM (0.25-20%) / EL (1%)

275 rpm, 2 h, 45°C

80 s, 40%

93 – 614

0.19 – 0.51

MCM (0.25-20%) / RH (1%)

275 rpm, 2 h, 45°C

80 s, 40%

61 – 511

0.25 – 0.58

WL (0.25-20%) / SL (1.2%)

15,000 rpm, 10 min, 30°C

3-4 min, 25-40%

88 – 390

0.11 – 0.38

WL (2.5-20%) / RH (10%)

275 rpm, 2 h, 45°C

N/A

73 – 603

0.25 – 0.92

WL (1.25-20%) / HS (10%)

275 rpm, 0.5 h, 45°C

5 min, 40%

82 – 504

0.13 – 0.52

WL (20-50%) / HS (0.25-

5,000-20,000 rpm, 2-10

2-6 min, 20%

175 – 1368

0.03 – 0.22

10%)

min, 30°C

SO: Soybean oil; SL: Soybean lecithin; RH: Kolliphor® RH40; TW: Tween® 80; HS:
Kolliphor® HS15; MCM: Capmul® MCM NF; F68: Pluronic F68; EL: Kolliphor® EL; WL:
LabrafacTM lipophile WL1349. N/A: Not applicable; PI: Polydispersity Index. Droplet size and
PI were determined at 100-fold dilution.

14

Table 2.2 Commercial name, chemical structure and HLB of
the selected ingredients
Commercial
name

Chemical structure

Description

Glyceryl caprylate/caprate;
Capmul®
MCM NF

Medium chain C8-, C10monoglyceride;
HLB= 5-6

Glyceryl tricaprylate/tricaprate;
TM

Labrafac
Lipophile
WL1349

Medium chain C8-, C10- triglyceride;
HLB=1

Polyoxyl 15 hydroxystearate;
Polyglycol mono- and di-esters of 12hydroxystearic acid and of about 30%
of free polyethylene glycol;

Kolliphor®
HS15

HLB = 14-16

HLB = Hydrophile-lipophile balance
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Table 2.3 Summary of the NE formulation and sonication specifications
Formulation

MCM
(mg)

WL (mg)

HS (mg)

Sonication specifications
H2O

Amplitude

On-duty time

(q.s., mg)

(%)

(min)

SE

250

250

500

5000

N/A

N/A

ME

N/A

1200

300

3000

20

6

LE

N/A

1200

15

3000

20

6

N/A = Not applied, MCM = Capmul® MCM NF, WL = LabrafacTM Lipophile WL1349, HS =
Kolliphor® HS15, SE = Small-sized NE, ME = Medium-sized NE, LE = Large-sized NE
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Figure 2.2 Droplet size distribution of SE, ME and LE. The droplet sizes were
determined for SE (grey, 30 ± 9 nm), ME (blue, 212 ± 64 nm) and LE (red, 893 ± 158 nm) by
dynamic light scattering at 100-fold dilution in distilled water to prevent multiple scattering. The
peaks were distinct to each other without overlapping to ensure proper interpretation of in vivo
results. Data were presented as the size distribution for one experimental.
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Table 2.4 SE, ME and LE mean droplet size and PI determined by DLS

(Mean ± SD, n=3)
Droplet size (nm)

PI

SE

29 ± 1

0.06 ± 0.02

ME

214 ± 2

0.11 ± 0.02

LE

883 ± 16

0.11 ± 0.10
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2.3. The stability tests for the NEs
2.3.1. Materials and methodology
The prepared NEs were subjected to the stability tests including stability during storage under
ambient temperature, stability against serial dilutions and stability in mice plasma in vitro.
For the stability at ambient temperature, the prepared NEs were sampled for DLS droplet size
determinations at 100-fold dilution in distilled water every 24 h for 3 days. The droplet size of SE
and ME was also measured at 3 months while LE was visually observed every day after 3 days
until phase separation occurred. For the stability against dilutions, the NEs were diluted 5-1000
folds in pH 7.4 phosphate buffer saline (PBS) prior to droplet size determination by DLS. For the
stability in mice plasma, 100 µL NEs (without dilution) was incubated with 100 µL mice plasma
(Rockland antibodies and assays, Pennsylvania) at 100 rpm, 37°C. At sampling time point, a 40
µL aliquot was sampled and diluted 50-fold in PBS prior to droplet size determination by DLS.

2.3.2. Results and discussions
2.3.2.1. NEs stability under ambient temperature
Figure 2.3 shows the droplet size change upon storage time at ambient temperature. Within 3
days, no significant droplet size changes were observed for all NEs. Notably, the droplet size
variation for LE started to increase as early as Day 2. Since NE by nature is kinetically stable but
thermodynamically unstable system (Gupta et al., 2016), the low concentration of HS in LE
resulted in a faster droplet aggregation which eventually led to the phase separation on Day 7. SE
and ME on the other hand, were much more stable up to the last observation time at 3 months.
Apparently, the ultrasonication played a critical role to stabilize the NEs especially LE which
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otherwise separated in less than 15 min without this process. Though LE had limited
thermodynamic stability, a 72-h stable system was sufficient for the purpose of the current study.

2.3.2.2. NEs stability against dilutions
Figure 2.4 illustrates the impact of dilutions on the NEs. SE presented a good stability with no
droplet size changes at all the tested dilution levels (5- to 1000-fold dilution) with the average
size ranging from 24 nm to 32 nm. ME demonstrated size variation at 5-fold dilution (110 ± 14
nm) and 10-fold dilution (155 ± 9 nm). Further dilution of ME from 50- to 1000-fold did not
cause significant change in size with the mean droplet size ranging from 187 nm to 219 nm. The
variations at lower dilution for ME and LE were likely due to the multiple scattering phenomenon
by DLS since they both had much higher lipid concentrations versus SE. Multiple scattering
refers to the phenomenon wherein photons scattered from the analyte are re-scattered from
neighboring particles prior to reaching the instrument detector (Malvern technical bulletin).
Therefore, this phenomenon occurs at higher particle concentration. The net result then, is that
DLS size measurements in the presence of multiple scattering will be biased toward smaller sizes.
LE showed variations in size upon dilution. Besides the size changes at lower dilution level (764
± 310 nm at 5-fold and 1249 ± 198 nm at 10-fold), the droplet size also showed significant
increase to 1782 ± 542 nm at 1000-fold dilution. This was probably because at this dilution level,
the relative concentration of HS was not enough to reduce the surface tension, which resulted in
the aggregation of the droplets. However, the LE droplet size appeared to be stable upon dilutions
from 20 to 500-fold. And the estimated dilution of the NE after i.v. injection is in this range.
Therefore, the stability of size at this range of dilution assures the LE size will not change due to
dilution by plasma in the in vivo studies.

20

2.3.2.3. NEs stability in mice plasma in vitro
As depicted in Figure 2.5, when incubated at 37 °C under mild shaking condition, ME and LE
did not show droplet size change for 4 h which could be attributed to the use of Kolliphor® HS15
(HS). HS is a PEGylated surfactant which comprises of 15 units of PEG monomer as the
hydrophilic head. Due to the high hydrophilicity, chain flexibility, electrical neutrality, PEG helps
to sterically stabilize NPs and prevent the interactions with biological components (Gref et al.,
1995; Avgoustakis, et al., 2003). Contrarily, SE droplet size increased from 1 h and became
comparable to that of ME after 4 h despite the use of HS. This could be due to the much smaller
size hence significantly larger surface area. The enhanced surface area might facilitate the
interactions between the droplets and plasma protein.
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Figure 2.3 The NEs stability under ambient temperature. At sampling time points, the
NEs were sampled and diluted 100-fold in distilled water prior to droplet size determination by
DLS. There was no droplet size change over 3 days for all three NEs. However, phase separation
(*) was observed for LE after 7 days post preparation. SE and ME did not show droplet size
change until 90 days (Mean ± SD, n=3).
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Figure 2.4 NEs stability against dilutions in pH 7.4 PBS. Freshly prepared NEs were
subject to different folds of dilutions in pH 7.4 PBS and the droplet sizes was determined by DLS
(Mean ± SD, n=3).
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Figure 2.5 NEs stability in mice plasma in vitro. NE were incubated with mice plasma at
37°C, 100 RPM in vitro. The droplet size was measured by DLS after 100-fold dilution in PBS
(Mean ± SD, n=3). *: Significantly different from the droplet size at time 0, P < 0.05.
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2.4. Summary
The NEs with distinct droplet sizes, i.e., the small-size NE (SE) of ~30 nm, the medium-size NE
(ME) of ~200 nm and the large-size NE (LE) of ~ 900 nm, respectively, were successfully
prepared. Unlike the NEs in the literature, these NEs, especially LE, demonstrated a narrow and
well-defined droplet size distribution. The corresponding peaks of the three NEs did not overlap
with each other so that they would not cause interference for the in vivo assessment. The NEs
were subject to various stability tests. The results suggested that all the NEs demonstrated
stability for at least 3 days when stored under ambient temperature. In addition, they were also
stable against 20- to 500-fold dilution in pH 7.4 PBS. When incubated with the mice plasma in
vitro, SE droplets tended to increase after 1 h whilst ME and LE maintained the initial droplet
size.
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Chapter 3. Establishment of DiI fluorometry and biological
sample preparation protocol

In this chapter, the following topics are addressed:
•

The development and validation of the fluorometry for DiI

•

The establishment of the in vivo animal model

•

The establishment of the preparation protocol and assay for biological samples

3.1. Introduction
Fluorescence dyes have found use in a wide spectrum of geological, biological and
pharmaceutical sciences. Compared to fluorescent proteins, they present smaller molecules, better
photostability and brightness, and the absence of maturation time (Süel et al., 2011). The
fluorescence marker technology can be used to determine a variety of substances such as
environmental pollutants, drugs, amino acids and nucleotides (Suzuki et al., 2015). The use of the
fluorescent dyes extends to immunofluorescence microscopy, flow cytometry, cellular staining,
tracking and intra-/inter-cellular trafficking, etc. In the field of nanotechnology, fluorescent dyes
have also seen extensive applications in the evaluations of in vivo biological fate of different
types of NPs such as polymeric NPs (Reisch et al., 2016), micelles (Wei, 2019) and liposomes
(Tansi et al., 2015), etc.
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The capabilities of a fluorescent dye used in the biological studies are mainly dependent on its
physical properties. The extinction coefficient (the extent to which a fluorophore absorbs light),
the quantum yield (the emission of fluorescence from an excited fluorophore) and the
photostability are among the most important considerations when selecting the dyes (Wells et al.,
1990). Some commonly used dyes in pharmaceutical research include fluorescein isothiocyanate
(FITC), rhodamines and lucifer yellow (LY), etc., each with advantages and limitations (Brelie,
1993). For example, FITC provides reasonably large extinction coefficient and high quantum
yields after conjugation with biological molecules, however it also associates with unfavorable
properties such as aqueous decomposition, limited photostability, pH-sensitivity and overlapping
emission spectrum with autofluorescence. Rhodamine, on the other hand, though more
photostable and pH-insensitive, poses significantly lower quantum yield thus much dimmer
fluorescent signals. Similarly, LY presents intense fluorescence and reasonable photostability
whilst the extremely broad excitation and emission spectra complicate its detection in the
presence of other fluorophores.
Besides the above fluorescent dyes, the group of carbocyanine dyes (cyanines) has been
developed and remained as the most prevalent fluorophores for in vivo imaging due to the long
excitation and emission wavelengths which are distinguished from most of the autofluorescence
generated by endogenous fluorophores from the body (Croce et al., 2014). Among the cyanine
family, DiI (1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine perchlorate, Figure 3.1), also
known as DiIC18(3), provides some features such as (1) It diffuses laterally within the entire cell
and subsequently well retained with little transfer to other cells; (2) It is weakly fluorescent in
water but highly fluorescent and photostable in lipid membrane; (3) It possesses very bright
signals with high extinction coefficients (Invitrogen, 2010); (4) It does not appreciably affect cell
viability, development, or basic physiological properties (Honig and Hume, 1989). Due to these
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properties, DiI has been used in cellular staining (Fallatah et al., 2019), in vivo cell tracing
(Endepols, 2001), ligand-receptor molecular transfer (Xu, 1992), etc. In addition, the water
insolubility of DiI potentially render its usefulness especially in labeling lipid-based drug delivery
system (LBDDS) such as NE. All these properties make DiI a good labeling candidate for the
current study. To the best of our knowledge, DiI has not yet been utilized as a quantitative
labeling agent for DDS. Therefore, it is important to establish DiI quantitative fluorometry
method and to evaluate its suitability for the in vivo study purpose.
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Figure 3.1 Chemical structure of DiI
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3.2. DiI fluorometry method establishment and validation
3.2.1. Materials and methodology
DiI was purchased from Biotium (Biotium Inc., CA). Dimethylsulfoxide (DMSO) was of reagent
grade (BDH, VWR). DiI Stock Solution (400 µg/mL) was prepared by the dissolution of DiI
crystals in DMSO. The Standard Working Solutions were subsequently prepared from the Stock
Solution to produce a DiI concentration range from 1.0 to 1000 ng/mL. Two hundred µL of the
Standard Working Solutions was added to a well of 96-well black microplate and the
fluorescence intensity was measured by a Glomax® Fluorescence Microplate Reader (San Luis
Obispo, CA, USA) with the high sensitivity mode at room temperature. The excitation and
emission wavelengths were 520 nm and 580-640 nm, respectively. The experiment was
conducted in triplicate. The fluorescence intensity was plotted versus the DiI concentrations to
obtain the standard calibration curve. The assay method was validated by accuracy and
intermediate precision. Briefly, the accuracy of the method was conducted by the determination
of a set of DiI solutions with known concentrations (5, 20, 50, 200 and 500 ng/mL). The
measured concentration was compared to the theoretical concentration to obtain the percentage
recovery. Intermediate precision was evaluated on different days to determine the relative
standard deviation (%RSD).

3.2.2. Results and discussions
Figure 3.2 shows the linear regression curve for DiI standard solutions. The assay method had a
linear range of 1.0 to 1000 ng/mL with a correlation coefficient of 0.9998 indicating a good
correlation between DiI concentration in DMSO and its corresponding fluorescence intensity. The
percentage recovery for the accuracy test of five known concentration standards (5, 20, 50, 200
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and 500 ng/mL) was found to be 95.7 ± 4.2% (Table 3.1). In addition, the intermediate precision
results indicated a 1.7% to 2.7% RSD (Table 3.2) throughout the concentrations within the linear
range. The data demonstrated that the established fluorometry method for DiI was valid and
reproducible. Furthermore, the lowest DiI concentration of 1.0 ng/mL which exhibited three times
signal-noise ratio was comparable to that of Rhodamine-B of 0.5 ng/mL (Huang et al., 2016) and
FITC of 2.2 ng/mL (Imasaka et al., 1977). This high sensitivity rendered practical use for the
analysis of in vivo biological samples in which compounds of interest are usually presented in the
concentration range of µg/mL, though the interference from the sample matrix should be
carefully evaluated.
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Figure 3.2 DiI standard calibration curve in DMSO (Mean ± SD, n=3).
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Table 3.1 Accuracy of DiI fluorometry method (Mean ± SD, n=3)
Nominal Concn.
(ng/mL)

Calculated Concn.
(ng/mL)

Recovery (%)

5

5.1 ± 0.1

101.8 ± 1.8

20

19.2 ± 0.6

96.0 ± 2.8

50

48.0 ± 0.3

96.1 ± 0.6

200

188.3 ± 1.3

94.2 ± 0.6

500

451.2 ± 9.6

90.2 ± 1.9

MEAN ± SD (n=5)
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95.7 ± 4.2

Table 3.2 Intermediate precision of DiI fluorometry method (n=3)
DiI Concn. (ng/mL)

RSD (%)

1

2.7

4

2.3

10

1.7

40

1.7

100

1.9

400

1.7

1000

1.9
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3.3. The characterizations of DiI
3.3.1. Materials and methodology
Mice plasma (directly from non-hemolyzed blood from healthy and fasted donor) was purchased
from Rockland Immunochemicals, Inc. (Pottstown, PA, USA) The stability of DiI in mice plasma
was evaluated by incubation of 100 µL of DiI Standard Solution in Ethyl Alcohol (40 µg/mL)
with 1.9 mL mouse plasma. The mixture was vortexed for 10 s and 10 µL aliquot was
immediately assayed to determine the DiI concentration at time 0. The plasma was then shaken at
200 rpm under 37°C in the dark. At each sampling time point (0.25, 0.5, 1 and 2 h), 10 µL aliquot
was diluted in DMSO prior to the fluorescence intensity measurement. DiI concentration at each
time point was presented as the percentage versus the concentration at time 0.
The solubility of DiI in WL was determined by the addition of an excessive amount of DiI in WL.
The mixture was shaken at 25°C for 72 hours. The mixture was subsequently centrifuged at
15,700 g for 5 min and the supernatant was properly diluted in DMSO prior to the fluorometric
assay.
The partition coefficient of DiI in WL and MCM versus water was evaluated. Briefly, one mg of
DiI was dissolved in 5 g of the lipids, respectively. Subsequently, equivalent volume of deionized
water was added, and the mixture was shaken at 37°C, 200 rpm for 24 hours. The mixture was
transferred to a separatory funnel to equilibrate and separate the two phases and each phase was
assayed for DiI after proper dilution in DMSO. The Log partition coefficient was calculated
based on the DiI concentration in each phase.
The above experiments were conducted in triplicate.
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DiI loaded NEs were prepared according to the formulations and subsequent preparation
procedures described in Section 2.1.1., except for that DiI was first dissolved in WL to achieve a
concentration of 2.5 mg DiI/g WL. The droplet size of DiI labeled NEs were measured by DLS at
100-fold dilution in pH 7.4 PBS.

3.3.2. Results and discussions
Figure 3.3 depicts the stability of DiI in mice plasma. There was no degradation of DiI in 2 h
indicating its photostability in mice plasma. In addition, DiI was characterized for lipophilicity.
DiI had a 5.51 ± 0.09 mg/g WL solubility. Figure 3.4 illustrates DiI partition coefficient between
WL/MCM and water. The high lipophilicity of DiI (log P = 4.31 ± 0.03, n=3) in WL versus water
ensured the complete encapsulation of the dye in the NE droplets. These findings together
suggested that DiI was a suitable fluorescent dye to label NEs. Finally, DiI was loaded into the
NEs. Figure 3.5 shows the visual appearance of the DiI loaded SE (DSE), DiI loaded ME (DME)
and DiI loaded LE (DLE), respectively. Table 3.3 summarizes the droplet size of DiI loaded NEs.
The NEs droplet size was not affected by the loading of DiI. DSE had a final DiI concentration of
0.2 mg/mL, whilst DME and DLE 1 mg/mL, respectively.
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Figure 3.3 DiI stability in mice plasma. DiI was incubated with mice plasma at 37°C for 2 h
in dark (Mean ± SD, n=3).
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Figure 3.4 Partition coefficient of DiI in WL and MCM versus water (Mean ± SD,
n=3).
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Figure 3.5 Photos of DiI-loaded NEs. DiI loaded SE (DSE, 0.2 mg/mL) had a transparent
appearance whilst DiI loaded ME (DME, 1 mg/mL) and LE (DLE, 1 mg/mL) were milky.
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Table 3.3 DSE, DME and DLE mean droplet size and PI determined by DLS

(Mean ± SD, n=3)
Droplet size (nm)

PI

SE

29 ± 2

0.06 ± 0.01

ME

197 ± 3

0.16 ± 0.02

LE

843 ± 101

0.34 ± 0.13
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3.4. Tumor-bearing mice model
3.4.1. Cell culture
RPMI 1640 medium with L-glutamine, Hanks’ balance salt solution (HBSS), MEM vitamin,
sodium pyruvate were purchased from Hyclone (Hyclone, UT). Fetal bovine serum
(MilliporeSigma, MA), non-essential amino acids (Sigma Aldrich, MO), trypsin/EDTA (ATCC,
VA), trypan blue (Nano Entek, South Korea), cell strainer (40 µm, Greiner Bio-One, Austria)
were purchased through VWR. The complete medium (CM) was prepared under sterile condition
according to Table 3.4 (Overwijk and Restifo, 2001)
B16F10 melanoma cell was purchased from the National Cancer Institute (NCI). Upon arrival,
the cell was rapidly thawed in 37°C water bath for 1.5 min until movement of ice clump occurred.
The cell suspension was diluted in CM and centrifuged at 660 g for 10 min at 4°C (Eppendorf
5804R, Germany). The cell pellet was resuspended in 3 mL CM which yielded 7.36×105 mL-1
with 92% viability determined by trypan blue staining using a hemocytometer (Countess II FL,
Life Technologies, CA). The cells were subcultured in CM at 37°C with 5% CO2 and were split
at 1:10 to 1:5 ratio when 50% confluent. Cells with more than 95% viability were cryopreserved
in 90% CM and 10% DMSO and stored in nitrogen vapor for future use.

3.4.2. Mice inoculation
Female C57BL/6J mice of 8-week old were purchased from Taconic Biosciences (Germantown,
NY) and housed at the Animal Care Center at St. John’s University. The mice inoculation
procedures were according to the protocol established by the NCI. (Overwijk and Restifo, 2001)
Briefly, B16F10 melanoma cells were harvested by trypsin/EDTA at less than 50% confluence to
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ensure the cells under logarithmic growth phase. Cells were resuspended in ice-cold HBSS and
passed through disposable cell strainer to remove clumps. The final concentration was adjusted to
1 × 106 cell/mL with a viability > 90%. The cell suspension 100 µL was injected subcutaneously
(105 cells/mouse) into the right flank of the mice. The tumor size was measured every day after 7
days by a caliper and calculated by Eq. (1):
Tumor size = ½ × L × W2

Eq. (1)

Where L was the length and W was the width of the tumor. (Tomayko and Reynolds, 1989)
When the tumor volume reached 120 mm3 or any dimension of the tumor measured 18 mm, the
further experiments were then carried out.

42

Table 3.4 The complete medium for B16F10 melanoma
Medium

Final concentration

Volume (mL)

RPMI1640 w/ L-glutamine

-

500

Fetal bovine serum (FBS)

10% v/v

55

100 µM

5.5

Sodium pyruvate (100 mM)

1 mM

5.5

MEM vitamin (100×)

-

7.5

Non-essential amino acids
(100×)
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3.5. Biological sample preparation and DiI extraction protocol
3.5.1. Materials and methodology
Subcutaneous B16F10 melanoma bearing female C57BL/6J mice were anesthetized by 2.5%
isoflurane inhalation. The blood was collected by cardiac puncture and then centrifuged at 2,000
g, 4°C for 10 min to obtain the plasma. The mice were then sacrificed by carbon dioxide
asphyxiation. The major organs including the heart, liver, spleen, lungs, kidneys, stomach, small
intestine, colon, brain and tumor were collected. The tissues were wiped, weighed and
homogenized by Pyrex® Tenbroeck homogenizer (Corning, NY) in deionized water at 1:4 or 1:9
(w/v). The tissue homogenate and plasma were spiked with DiI standard solution by a HPLC
manual syringe (ThermoFisher Scientific, Waltham, MA) at 0.1, 1, 10 and 50 µg*g-1 (DiI/tissue),
respectively. Non-spiked tissue homogenates were used as the blank references. The spiked
homogenates were extracted by two protocols. In the first protocol, equivalent volume of Ethyl
Acetate (EA) was added to the homogenate, and the mixture were vortexed at 2,000 rpm for 30
min (Scientific Industries, NY) followed by centrifugation at 15,700 g for 5 min. The supernatant
was diluted in DMSO and subjected to the fluorometry method. In the second protocol,
equivalent volume of EA was added to the homogenate, and the mixture was vortexed at 2,000
rpm for 10 min followed by centrifugation at 15,700 g for 5 min. The supernatant was collected
and replaced by equivalent volume of EA. The mixture was vortexed again at 2,000 rpm for 10
min and centrifuged with the same condition to obtain the second supernatant. Both aliquots of
the supernatant were diluted respectively in DMSO prior to fluorescence measurement. The
extraction efficiency was presented as the percentage recovery of DiI. The experiments for the
two protocols were individually conducted for at least three times. One-way analysis of variance
(ANOVA) and two-tail paired t-test were conducted and a P < 0.05 was considered as
significantly different.

44

3.5.2. Results and discussions
The mice were inoculated with 105 B16F10 melanoma subcutaneously. Tumor became visible
usually after 7 days and reached 120 mm3 in 10 to 14 days. To evaluate the extraction efficiency
of DiI from various biological samples, we investigated two extraction protocols. The first
protocol involved a single extraction on the spiked or blank tissues for 30 min (Figure 3.6) whilst
the second protocol utilized a double extraction each for 10 min (Figure 3.7). Despite the longer
total vortex time in the single extraction method, DiI recovery from all the biological samples fell
in the range from 60 to 75% with the RSD ranging mainly from 10.9% to 24.9%. Nevertheless,
when the double extraction was applied, though the total vortex time was shortened, DiI recovery
were found mainly above 80% and for certain tissues over 90% with the RSD ranging mainly
from 3.2% to 11.3%. This contrast suggested the double extraction protocol was capable of
extracting DiI more efficiently and precisely from the various biological samples.
Due to the complexity of in vivo biological sample matrix and the autofluorescence from various
endogenous fluorophore (Croce and Bottiroli, 2014), it was important to evaluate and eliminate
such interferences. The blank tissues therefore served for this purpose and underwent the same
extraction protocols. The results showed that the EA extracts showed similar signal as the blank
solvent reading which suggested the good specificity of the extraction protocols and the
developed fluorometry.
Statistical analysis was performed for the double extraction method to investigate whether there
were differences among concentration levels for a given tissue and if there were differences
among tissues within a given concentration level. The results demonstrated there was no
significant difference in the mean extraction ratio of any given tissue among the concentration
groups (0.1, 1, 10 and 50 µg/g tissue). This indicated the extraction method was consistent and
reliable to extract DiI at least within the tested concentration range. However, various tissue
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spiked with the same concentration of DiI exhibited different mean extraction ratio from 70.2% to
97.0%. Such difference could be due to the difference of the lipophilic compositions in the tissue.
For example, glial cells and lipophilic endocannabinoids are mostly abundant in the central
nervous system (Scheller and Kirchhoff, 2016). In contrast, the stomach is uniquely comprised of
three layers of highly content of smooth muscle. Due to such tissue variance, the grand mean
(n=12) of the extraction ratio from a certain tissue was determined and would be further used
individually as shown in Table 3.5.
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Table 3.5 DiI extraction efficiency from biological tissues
(Mean ± SD, n=12)
Tissue

Extraction efficiency (%)

Heart

79.5 ± 3.0

Liver

76.8 ± 1.2

Spleen

82.6 ± 4.1

Lungs

83.0 ± 2.6

Kidneys

87.0 ± 2.5

Stomach

74.6 ± 3.2

Small Intestine

80.2 ± 2.4

Colon

78.5 ± 2.0

Brain

93.4 ± 1.0

Tumor

84.3 ± 4.2

Plasma

90.1 ± 2.9
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Figure 3.6 Biological sample DiI extraction ratio by the single extraction protocol
(Mean ± SD, n=6).
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Figure 3.7 Biological sample DiI extraction ratio by the double extraction protocol
(Mean ± SD, n=3). There was no significant difference of the extraction ratio from a
given tissue among concentration groups. However, tissues within the same concentration
group exhibited different mean extraction ratios.
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3.6. Summary
A fluorometry method for DiI was established and validated for accuracy and intermediate
precision. DiI demonstrated high sensitivity with a linear range of 1.0 to 1000 ng/mL. DiI was
characterized for its lipophilicity, with a log P of 4.31 and 2.00 in WL/H2O and MCM/H2O
system, respectively. The stability of DiI in mice plasma was investigated in vitro and found to be
stable for the 2-h experimental period. In addition, DiI-loaded NEs were prepared, which showed
same droplet size and stability as the blank NEs. Furthermore, B16F10 melanoma bearing
C57BL/6J mice model was established. Finally, the biological sample preparation and DiI
extraction protocol were developed and evaluated. DiI extraction ratio from various tissues was
determined to be 79.5% for the heart, 76.8% for the liver, 82.6% for the spleen, 83.0% for the
lungs, 87.0% for the kidneys, 74.6% for the stomach, 80.2% for the small intestine, 78.5% for the
colon, 93.4% for the brain, 84.3% for the tumor and 90.1% for the plasma.
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Chapter 4. The in vivo biodistribution of the DiI-loaded
nanoemulsions
In this chapter, the following topics are elaborated:
•

The in vivo biodistribution experimental procedure and bioassay

•

DiI concentration-time profiles in various tissues after intravenous injection of DiI
solution (DS), DSE, DME and DLE

•

The interpretation of the biodistribution data and the evaluation of NE size-dependent
biodistribution

4.1. Materials and methodology
Female C57BL/6J mice of 8-week old were purchased from Taconic Biosciences (Germantown,
NY) and housed at the Animal Care Center at St. John’s University. The mice were inoculated
with B16F10 melanoma subcutaneously according to Section. 3.4.2. When the tumor volume
reached 120 mm3 or any dimension of the tumor measured 18 mm (usually in 10 to 14 days), the
following experiments were carried out. The mice were randomly and evenly divided into 4
groups (21 mice/group). The mice were restrained in a mice restrainer, and then injected through
the tail vein with DiI solution in 19% ethanol (DS), DSE, DME and DLE at the DiI dose of 5, 2, 5
and 5 mg/kg, respectively. Sterile dextrose for injection (5%) (D5W, Baxter, IL) was used as the
diluent in the formulations instead of distilled water. DSE was given at a lower dose due to its
higher viscosity not suitable for direct intravenous administration thus a dilution was performed.
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At each sampling time point (0.25, 0.5, 1, 2, 4, 6 and 10 h) post injection, three mice from each
group were anesthetized with 2.5% isoflurane inhalation. The blood was collected by cardiac
puncture and centrifuged at 2,000 g, 4 °C for 10 min to obtain the plasma (P). The mice were then
immediately euthanized by carbon dioxide asphyxiation. The major organs including heart (H),
liver (V), spleen (S), lungs (L), kidneys (K), stomach (T), small intestine (I), colon (C), brain (B)
and tumor (U) were collected and all the biological samples were stored under -20 °C until
analysis.
DiI concentration in the biological samples was determined by the established protocol (See
Section 3.5.). Briefly, the organs were weighed and homogenized with deionized water at 1:4,
w/v. Two hundred and fifty µL of the homogenized sample was mixed with equivalent volume of
EA and vortexed for 10 min at 2000 rpm followed by centrifuge at 15,700 g for 5 min. The
supernatant was collected and replaced by equivalent volume of fresh EA. The mixture was
vortexed for another 10 min at 2,000 rpm and a subsequent 5-min centrifuge at 15,700 g to obtain
the second supernatant. Both aliquots of the supernatant were then diluted in DMSO and subject
to the fluorometry method. DiI concentration in tissues was determined by the corresponding
tissue extraction ratio (See Table 3.5) and the concentration-time profile was plotted.
The major pharmacokinetics (PK) parameters were calculated by Phoenix® WinNonlin®
(Certara, NJ). One-way analysis of variance (ANOVA) and two-tail paired t-test were conducted
where applicable and a p < 0.05 was considered as significantly different.

4.2. DiI concentration-time profiles in tissues
Figure 4.1 through Figure 4.4 depict the DiI concentration-time profiles in various tissues
followed by the administration of DS, DSE, DME and DLE, respectively. The comparison and
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discussions in the following sections will be mainly focused on the observed concentrations and
the apparent maximum concentrations (Cmax). Lists of the calculated PK parameters such as area
under the curve (AUC), mean residence time (MRT) and detailed discussions, can be found in the
Appendix.

4.2.1. DiI tissue concentration-time profiles after i.v. administration of DS
As a lipophilic compound with small molecular weight, DiI showed a rapid concentration decline
in the plasma when given in the solution form (Figure 4.1). After 2 h, it was completely cleared
from the plasma. Such fast plasma clearance could be partially due to the rapid tissue distribution,
evidenced by the higher than plasma concentration in the liver, spleen and lungs at as early as the
first sampling time point (0.25 h). It could also be possibly due to the partial precipitation of DiI
upon instant dilution in the plasma. DiI concentrations in these tissues all peaked within 0.5 h
with apparent Cmax of 16.34, 32.68 and 15.52 µg/g in the liver, spleen and lungs, respectively. In
addition, a remaining DiI concentration was observed within these tissues in the late stage which
could be due to the portion uptaken by the tissues and this process could be implemented by the
two 18-carbon chains which firmly anchor in the cell membrane (Honig and Hume, 1986). On the
other hand, it was observed that the distribution of DiI in heart, kidney, stomach, small intestine,
colon and tumor was much less than that in liver, spleen and lung, with the apparent Cmax in these
tissues ranging from 0.23–2.74 µg*g-1.

4.2.2. DiI tissue concentration-time profiles after i.v. administration of DSE
When DSE was administered intravenously to the mice, DiI plasma concentration dropped
quickly but maintained, though low, at a constant level throughout the experiment period (Figure
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4.2). Such “sustaining” effect was also seen in the various tissues: DiI concentrations showed
more or less stable levels up to 10 h despite their peak concentrations occurred almost all early at
0.25 h. In certain tissues such as the liver, spleen, stomach, colon and tumor, the DiI
concentration at last sampling point (10 h) was higher than the previous one, indicating that the
terminal elimination phase had not been reached at the end of the experiment (10 h). In addition,
the apparent Cmax in liver and spleen was 1.44 and 1.13 µg*g-1, respectively, which were higher
than the apparent Cmax in other tissues (0.08–0.74 µg*g-1).

4.2.3. DiI tissue concentration-time profiles after i.v. administration of DME
Different from the rapid plasma clearance after administration of DS and DSE, DiI plasma
concentration demonstrated a much slower decrease rate when it was incorporated in the DME
(Figure 4.3). The estimated initial plasma concentration at time zero was 29.19 µg*mL-1, which
dropped down but then maintained at about 20 µg*mL-1 during the period of 0.25–1 h, and at
about 6–8 µg*mL-1 during the period of 2–10 h. This prolonged plasma level rendered more
chance and/or time of DiI to be distributed and accumulated in various tissues. As the result, high
tissue concentrations were observed at late stage, with the concentration-time profile in a few
tissues (liver, spleen, small intestine, colon and tumor) not reaching the final elimination phase at
the end of the experiment (10 h), the Tmax in liver, spleen and tumor being 10 h.
DME mainly distributed to the liver, spleen and lungs. The apparent Cmax in these tissues are in
the order of lung > spleen > liver (37.39–20.65 µg*g-1). These apparent Cmaxs were much higher
than the apparent Cmax in other tissues (0.46–10.01 µg*g-1), but similar as the estimated Cmax in
plasma (29.19 µg*mL-1). The apparent Cmax in heart was 10.01 µg*g-1, which was in the middle
between the apparent Cmaxs of the highly distributed tissues and the slightly distributed tissues
ranging from 0.46–3.83 µg*g-1.
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4.2.4. DiI tissue concentration-time profiles after i.v. administration of DLE
From the concentration-time profiles (Figure 4.4), it can be seen that after the administration of
DLE the plasma concentration decreased from the estimated 0-time 39.43 µg*mL-1 to about 20
µg*mL-1 at 0.5 h and then remained around 10–15 µg*mL-1 during the period of 1–4 h, and
thereafter became almost zero. In most tissues, DiI concentration peaked at 2 h, and diminished to
almost zero at 6 h, which was correlated with the plasma profile.
The organs with the highest distribution of DiI were spleen, lung and liver. The apparent Cmax in
these organs was 69.44, 41.53 and 28.91 µg*g-1, respectively, which were higher than the Cmax in
the other tissues (0.66–5.63 µg*g-1), but close to the estimated apparent Cmax in plasma (39.43
µg*mL-1). Among the lowly distributed tissues, the apparent Cmax in heart and kidney was 5.63
and 4.85 µg*g-1, respectively, which were still much higher than the apparent Cmax in brain, colon,
small intestine, stomach and tumor (0.66-2.27 µg*g-1).

In summary, based on the DiI concentration-time profiles in the tissues followed by the
intravenous administration of DS, DSE, DME and DLE, a common observation for each
formulation was that DiI preferably distributed to the RES organs including the liver, spleen and
lungs. The heart and kidneys, on the other hand showed much less DiI accumulation though they
are highly perfused. Furthermore, the stomach, small intestine, colon and brain showed limited
exposures to DiI, presumably due to the less blood flow or because of the blood brain barrier.
Finally, DiI did not show significant distribution in the tumor tissue with the exception of the case
by DME administration. In the following sections, further interpretation of the distribution
patterns and the comparison among the formulations will be discussed.
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Figure 4.1 DiI tissue concentration-time course after intravenous bolus injection of 5
mg/kg DiI in solution (DS) in C57BL/6J mice (Mean ± SEM, n=3).
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Figure 4.2 DiI tissue concentration time course after intravenous bolus injection of 2
mg/kg DiI loaded in small-size nanoemulsion (DSE) in C57BL/6J mice (Mean ± SEM,
n=3).
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Figure 4.3 DiI tissue concentration time course after intravenous bolus injection of 5
mg/kg DiI loaded in medium-size nanoemulsion (DME) in C57BL/6J mice (Mean ±
SEM, n=3).
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Figure 4.4 DiI tissue concentration time course after intravenous bolus injection of 5
mg/kg DiI loaded in large-size nanoemulsion (DLE) in C57BL/6J mice (Mean ± SEM,
n=3).
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4.3. The comparison between individual NE versus solution in various tissues
To illustrate the impact of NEs with different droplet sizes and how they alter the PK and
biodistribution of the loaded DiI, the DSE, DME and DLE were first individually compared with
the free solution. Figure 4.5 through Figure 4.15 present the DiI concentration-time profiles of
the four formulations in each tissue.

4.3.1. The plasma
Figure 4.5 depicts the plasma profiles after the administration of DS, DSE, DME and DLE. It can
be seen that DSE and DS resulted in very similar plasma profiles, with the consideration that the
DSE had only less than half of the dose as DS. However, DME resulted in significantly (p < 0.05)
higher plasma concentrations than DSE and DS at all the sampling time points except for at 1 h
(yet about 20-fold higher). And DLE caused the similar plasma profile as DME except at the last
two time points, where the plasma concentration decreased almost to zero as the DSE and DS.
The phenomenon that the free solution dosage form (DS) resulted in much lower plasma
concentration profile than DME and DLE could be due to multiple reasons (the low plasma
concentration profile of DSE compared to DME and DLE is discussed in Sections 4.4.2.). First
and most possibly, the free DiI was rapidly cleared from the plasma. As discussed previously, the
liver, spleen and lungs already showed higher DiI concentrations at 0.25 h than that of the plasma
indicating a fast distribution had occurred. The extrapolated Cmax at time 0 for DS, DME and DLE
was 24.01, 29.19 and 39.43 µg/mL, respectively. These similar 0–time concentrations were
expected as the doses were same. However, there were significant differences in concentrations at
0.25 h and further time points indicate the possibility of the fast plasma clearance of DiI given as
free solution. Secondly, a portion of DiI in the ethanol solution could immediately precipitated
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because of the quick dilution in the blood after administration. Another possibility was that a
portion of DiI partitioned into the cellular components of the blood which was therefore excluded
from the plasma assay. But this was unlikely to happen when DS was given due to the slow
staining rate of the dye into live tissues, not to mention in the dynamic flow of the blood stream
(Invitrogen, 2010).

4.3.2. The heart
As shown in Figure 4.6, DiI peaked fast within 0.5 h followed by a rapid clearance from the heart
resulting negligible concentration after 1 h when given in the DS. DSE demonstrated comparable
concentration course in the heart as DS. Contrarily, DME and DLE, especially the former one,
increased significantly the apparent Cmax of DiI in the heart, being 1.1-fold and 2.7-fold increase
for DLE and DME, respectively. Since the heart is mostly comprised of myocardium and the
blood perfusion is the major determinant for drug distribution into its tissue, the drug
concentration in the heart usually correlates well with the corresponding heart concentration when
given as the free solution form. The modification by drug delivery system could sometimes lead
to the change in the PK of the drug in the heart, such as the case of the liposomal Doxorubicin
(Papahadjopoulos et al., 1991). In the current study, increased DiI concentration was observed in
the heart at each time point followed by DME administration, compared to the solution or other
NEs. To the best of our knowledge, there lacks literature report on the heart distribution of NEs
prepared with HS. It has been reported, however, that HS based micellar solutions altered the
encapsulated drugs heart disposition as compared to the free drug solutions, though the results
were somewhat contradictory (Ma et al., 2012; Lu et al., 2014). Therefore, at this point, it is hard
to give an explanation on the favorable heart accumulation by DME. Nevertheless, this
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observation is worth of further investigation and could possibly arise as a heart targeting drug
delivery strategy.

4.3.3. The liver, the spleen and the lungs
The comparison for distribution in the liver, spleen and lungs tissues are grouped and discussed
together (Figure 4.7, 4.8 and 4.9), as they are all highly perfused and also abundant with the RES
thereby responsible for the particulate matters clearance, though the lungs play this role to a lesser
extent (Baas et al., 1994). Indeed, DiI was mainly recovered from these tissues regardless of the
formulations. However, when DME and DLE were administered, there was a further remarkable
increase of the DiI distribution in these tissues as compared to the DS.
It is interesting to see that the pattern of the concentration-time profile following DS
administration was different from those after DME and DLE administration. The apparent peak
concentration after DS administration occurred at 0.25 h (lung) and at 0.5 h (liver and spleen),
and then rapidly decreased to negligible level at 2 h. This was probably due to 1) fast distribution
of DiI as in a solution form into these tissues, and 2) DiI precipitated out after dosing in the blood
circulation and the precipitate was captured by the RES system. And then DiI was quickly
metabolized in these organs, especially maybe in the liver. The apparent peak concentration after
DME and DLE administration reached at later time period than DS, which represented gradual
accumulation in the organs of DiI when delivered in NE form which prolonged the residence time
in the blood circulation. This was supported by the comparison of apparent plasma Cmaxs, since
compared to DS, DME and DLE increased the plasma Cmax only 1.2- and 1.6-folds, respectively
(Figure 4.16).
Another interesting finding was observed from DSE. As mentioned earlier, unlike DME and
DLE, DSE did not achieve significant increase in plasma exposure as compared to DS. In fact,
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DSE actually decreased spleen and lungs exposures as compared to DS. The apparent Cmax in the
liver, spleen and lungs decreased by 78%, 91.4% and 92.3%, respectively. In addition, DiI was
not significantly recovered from the other tissues after DSE administration. The following
discussion may help to explain this phenomenon.
As demonstrated by Braet et al., noncontinuous endothelia with vascular fenestrations measuring
50 to 100 nm is present in the liver which leads to nonspecific accumulation of particles larger
than that (Braet et al., 2007). Similarly, splenic filtration accounts for retention of particles bigger
than 200 nm, due to the 200-500 nm size range of inter-endothelial cell slits (Chen and Weiss,
1973). The lung capillaries have even larger size cutoff in the micrometer range (2 to 5 μm).
Although these are human anatomy parameters and no mouse parameters are found in the
literature, it could be reasoned that the ~30 nm DSE might pass through the intercellular
fenestrations in these mouse tissues freely, resulting significant lower accumulation. The present
finding is in agreement with Attia et al. in whose study the NE with 55-nm size yielded reduced
in vivo hepatic toxicity in rats and the authors attributed this to the reduced cellular uptake of the
NE observed in vitro (Attia et al., 2016).

4.3.4. The kidneys
The distribution of DiI into the kidneys was generally low for all the formulations. DLE achieved
the highest apparent Cmax around 5 µg*g-1, followed by DME (~4 µg*g-1), DS (~1 µg*g-1) and
DSE (<1 µg*g-1). The apparent Tmax was 0.25, 0.5, 0.5 and 2 h for DSE, DS, DME and DLE,
respectively. DME maintained the concentration within the range of 0.94-1.77 µg*g-1 during the
period of 6-10 h, while the other three resulted in negligible concentrations.

63

4.3.5. The stomach, the small intestine, the colon and the brain
The rest body tissues under investigation including the gastrointestinal tract (GIT) tissues and the
brain were grouped and discussed together as they all showed limited DiI exposure (Figure 4.11
through Figure 4.14). DS resulted in the concentration in the range of 0.11-0.40 µg*mL-1 in all
the GIT tissues. DSE resulted in the concentration range in the GIT tissues similar to that by DS.
DME and DLE achieved relatively higher concentration than DS, but still only in the range of
0.30-2.35 µg*g-1 in the GIT tissues. Compared to DS, DME increased the apparent Cmax in the
GIT tissues by 2.5-6.8 folds, and DLE achieved 1.8-4.0- fold increase. The overall low DiI
distribution into these GIT tissues was probably because of the low blood perfusion.
The distribution of DiI in the brain tissue was even lower than that in the GIT tissues for all the
three NEs, with the majority concentrations being less than 0.2 µg*g-1. The apparent Cmax by
DME and DLE was 0.46 and 0.66 µg*g-1, respectively, while only 0.1 µg*g-1 by DSE. Since the
brain DiI concentration after the administration of the DS was not determined, it is impossible to
compare DS vs the three NEs. Nevertheless considering the brain has a moderate to high blood
perfusion similar as that of the liver (Gjedde and Gjedde, 1980), the absolute low DiI distribution
in brain after the i.v. administration of the NEs indicates that the blood brain barrier (BBB)
played a major role to prevent the NE droplets from entering the central nervous system (CNS).

4.3.6. The tumor
In the current study, DiI accumulation in the subcutaneous B16F10 melanoma was also studied to
evaluate the potential formulation benefit for the enhanced tumor targeting effect. In general, the
distribution of DiI in the tumor was low for all the formulations. DSE resulted in similar
concentration profile (below 0.5 µg*g-1 throughout the entire experimental time) as DS. DLE
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caused a 4.8--fold increase in apparent Cmax, as compared to DS. DME further profoundly
enhanced DiI tumor disposition demonstrated by a 7.7- fold improved Cmax. Notably, DiI peaked
in the tumor at 2 h post the injection of DLE and then dropped to negligible level at 6 h and 10 h.
However, following DME administration, the accumulation in tumor continued to the last
sampling point, resulted in the highest concentration (3.01 µg*g-1) at the end of the experiment.
It has been well known that to fully utilize the EPR effect for NPs accumulation in tumor through
passive diffusion, the prerequisites are first an optimal particle size to exert enhanced permeation
as well as reduced lymphatic drainage, and secondly a sufficiently long circulation time to carry
out such accumulation (Ma et al., 2012). As DME possesses both of the features of ~200 nm in
size and the longest plasma circulation evidenced by the significant higher plasma concentration
at the last sampling point, it indeed showed the most significant tumor uptake as compared to the
other three dosage forms.

As the summary of Section 4.3, NEs altered the biodistribution of DiI to various degrees.
Compared to DS, DSE caused a minimum increase in biodistribution in some tissues but decrease
in other tissues. However, DME and DLE enhanced the biodistribution in all tissues with
remarkable increase in several tissues. Therefore, in the next section, the three NEs are compared
to further elucidate the formulation impact on the NE biodistribution patterns.
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Figure 4.5 DiI concentration-time course in the plasma after intravenous bolus
injection of DiI solution (DS, 5 mg DiI/kg), small-size nanoemulsion (DSE, 2 mg
DiI/kg), medium-size nanoemulsion (DME, 5 mg DiI/kg) and large-size nanoemulsion
(DLE, 5 mg DiI/kg). (Mean ± SEM, n=3; Significantly different from DS (a) and DLE
(b), p < 0.05)
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Figure 4.6 DiI concentration-time course in the heart after intravenous bolus injection
of DiI solution (DS, 5 mg DiI/kg), small-size nanoemulsion (DSE, 2 mg DiI/kg),
medium-size nanoemulsion (DME, 5 mg DiI/kg) and large-size nanoemulsion (DLE, 5
mg DiI/kg). (Mean ± SEM, n=3; Significantly different from DS (a) and DLE (b), p <
0.05)

67

40
35

a

a

Liver
DS
DSE

DiI Concentration (µg/g)

30
25

DME
DLE
a,b

20
15
10
5
0
0.25

0.5

1

2

4

6

10

Time (h)

Figure 4.7 DiI concentration-time course in the liver after intravenous bolus injection
of DiI solution (DS, 5 mg DiI/kg), small-size nanoemulsion (DSE, 2 mg DiI/kg),
medium-size nanoemulsion (DME, 5 mg DiI/kg) and large-size nanoemulsion (DLE, 5
mg DiI/kg). (Mean ± SEM, n=3; Significantly different from DS (a) and DLE (b), p <
0.05)
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Figure 4.8 DiI concentration-time course in the spleen after intravenous bolus
injection of DiI solution (DS, 5 mg DiI/kg), small-size nanoemulsion (DSE, 2 mg
DiI/kg), medium-size nanoemulsion (DME, 5 mg DiI/kg) and large-size nanoemulsion
(DLE, 5 mg DiI/kg). (Mean ± SEM, n=3; Significantly different from DS (a) and DLE
(b), p < 0.05)
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Figure 4.9 DiI concentration-time course in the lungs after intravenous bolus injection
of DiI solution (DS, 5 mg DiI/kg), small-size nanoemulsion (DSE, 2 mg DiI/kg),
medium-size nanoemulsion (DME, 5 mg DiI/kg) and large-size nanoemulsion (DLE, 5
mg DiI/kg). (Mean ± SEM, n=3; Significantly different from DS (a) and DLE (b), p <
0.05)
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Figure 4.10 DiI concentration-time course in the kidneys after intravenous bolus
injection of DiI solution (DS, 5 mg DiI/kg), small-size nanoemulsion (DSE, 2 mg
DiI/kg), medium-size nanoemulsion (DME, 5 mg DiI/kg) and large-size nanoemulsion
(DLE, 5 mg DiI/kg). (Mean ± SEM, n=3; Significantly different from DS (a) and DLE
(b), p < 0.05)
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Figure 4.11 DiI concentration-time course in the stomach after intravenous bolus
injection of DiI solution (DS, 5 mg DiI/kg), small-size nanoemulsion (DSE, 2 mg
DiI/kg), medium-size nanoemulsion (DME, 5 mg DiI/kg) and large-size nanoemulsion
(DLE, 5 mg DiI/kg). (Mean ± SEM, n=3; Significantly different from DS (a) and DLE
(b), p < 0.05)
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Figure 4.12 DiI concentration-time course in the small intestine after intravenous
bolus injection of DiI solution (DS, 5 mg DiI/kg), small-size nanoemulsion (DSE, 2 mg
DiI/kg), medium-size nanoemulsion (DME, 5 mg DiI/kg) and large-size nanoemulsion
(DLE, 5 mg DiI/kg). (Mean ± SEM, n=3; Significantly different from DS (a) and DLE
(b), p < 0.05)
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Figure 4.13 DiI concentration-time course in the colon after intravenous bolus
injection of DiI solution (DS, 5 mg DiI/kg), small-size nanoemulsion (DSE, 2 mg
DiI/kg), medium-size nanoemulsion (DME, 5 mg DiI/kg) and large-size nanoemulsion
(DLE, 5 mg DiI/kg). (Mean ± SEM, n=3; Significantly different from DS (a) and DLE
(b), p < 0.05)
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Figure 4.14 DiI concentration-time course in the brain after intravenous bolus
injection of small-size nanoemulsion (DSE, 2 mg DiI/kg), medium-size nanoemulsion
(DME, 5 mg DiI/kg) and large-size nanoemulsion (DLE, 5 mg DiI/kg). (Mean ± SEM,
n=3)
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Figure 4.15 DiI concentration-time course in the tumor after intravenous bolus
injection of DiI solution (DS, 5 mg DiI/kg), small-size nanoemulsion (DSE, 2 mg
DiI/kg), medium-size nanoemulsion (DME, 5 mg DiI/kg) and large-size nanoemulsion
(DLE, 5 mg DiI/kg). (Mean ± SEM, n=3; Significantly different from DS (a) and DLE
(b), p < 0.05)
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Figure 4.16 The comparison of dose normalized DiI apparent maximum
concentrations (Cmax) in various tissues after intravenous bolus injection of DiI loaded
small-, medium- and large-size nanoemulsion (DSE, DME and DLE) versus DiI solution
(DS), respectively.
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4.4. Discussions on O/W NE biodistribution upon intravenous administration
4.4.1. Potential factors contributed to the NE biodistribution
In the literature, extensive research has been conducted to study the factors which may impact the
PK and biodistribution of solid NPs. The particle size, shape/morphology, surface charge,
PEGylation and targeting ligands of the NP are widely known factors which determine the in vivo
behavior of the NPs (Alexis et al., 2008; Ernsting et al., 2013; Blanco et al., 2015). Therefore, it is
necessary to discuss the variables involved in the current study which might contributed to the
NEs biodistributions.
Firstly, the shape of the liquid droplets was spherical in nature which should not be a concern.
Secondly, the non-ionic surfactant HS was used without other ligands associated throughout all
the NEs in the current study. The exclusive use of HS herein as the sole surfactant helped to
minimize the effect from the droplet surface related variables. Notably, unlike solid NPs, it was
not practical to obtain NEs with different droplet sizes yet at same surfactant concentrations,
hence the inconsistent PEG concentration on the droplet surface of the developed NEs could have
impact on their biodistributions.
Besides the previous factors, the number of the droplets administered could also be a variable
thus deserves a discussion. It has been reported that the highest ever tested single injected lipid
dose for Intralipid® 10% was 10 g/kg (i.e., 1% mice weight) which was well tolerated by the
mice, and because of that even higher dose was irrelevant to be tested (Product monograph for
INTRALIPID® lipid injectable emulsion). This could probably explain why the approaches taken
in the literature when studying the NPs size effect on biodistribution universally used constant
drug/dye dose or surface area rather than the number of the NPs, as the number of NPs commonly
administered falls far below the threshold the animals could tolerate. Similarly, the total lipid
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used in the current study did not exceed 0.2% of the mice body weight, which makes it
reasonable to assume that the lipid given also follows linear kinetics where the number of
droplets would not impact on distribution. Moreover, the comparison of the three NEs in the
current study shows no correlation between biodistribution and number of droplets. In general,
the trend of the biodistribution change from DSE (with largest number of droplets) to DME was
opposite to that from DME to DLE (with fewest number of droplet). For example, both DSE and
DLE exhibited lower heart concentrations than DME.
Based on the above discussion, the biological fate of the studied NEs should therefore be possibly
impacted by their droplet size and the surface PEG density combinedly and the factors are related
to each other and cannot be completely separated.

4.4.2. The biodistribution of SE
As discussed previously, though DSE had a dose normalized apparent Cmax comparable to other
NEs, it contrarily showed limited plasma exposure. Neither did it accumulate in the RES tissues
including the liver, spleen and lungs. In addition, the other tissues under investigation did not
manifest major DiI recovery. Hence, the question where DSE has distributed in the body needs an
answer. Since the renal filtration cutoff size is 5.5 nm (Choi et al., 2007) and even considering the
mice kidney glomeruli pore radius as large as 9.6 nm (Jeansson and Haraldsson, 2003), DSE is
still much larger in size which excludes the possibility by glomerular filtration. Herein, the
following two kinds of possible in vivo fate of DSE are proposed.
Moghimi et al. demonstrated that the endothelium of bone marrow sinusoids could remove
particles from circulation by intercellular routes through the fenestrate in the endothelial wall and
this route was strongly dependent on the particle size (Moghimi, 1995) because the size of the
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fenestrate was reportedly 85-150 nm (Huang, 1971). Non-targeting liposomes were demonstrated
to accumulate three-fold higher in bone marrow of dog when their size was reduced from 1200 to
400 nm (Schettini et al., 2006). Similarly, non-ionic poloxamer-407 coated polymeric NPs less
than 150 nm in size were found to have an enhanced bone marrow disposition in rabbits (Porter et
al., 1992). As DSE is much smaller than these NPs in the literature, chances were that the
majority of the droplets could pass through the fenestrations presented in the RES organs which
resulted in the reduced accumulation in these tissues. Also considering the blood flow rate
through the capillary bed in the bone marrow is 51 mL*(100 g)-1*min-1 in the rabbit (Cumming,
1962) which is as rapid as the perfusion of 54 mL*(100 g)-1*min-1 into the brain (Kety and
Schmidt, 1946), DSE could possibly show significant disposition in the bone marrow.
The second hypothesis is associated with the fenestrations presented in the blood vessel
epithelium. There are three main types of endothelium: continuous (lacking fenestrations),
fenestrated and discontinuous (Risau, 1998; Robert and Palade, 2000). The fenestrations are more
abundant in the endothelium of organs where a higher rate of exchange between intra- and
extravascular compartments is required, such as in the gastrointestinal or peritubular renal
capillaries (Simon and Filip, 2009). These fenestrations retain permeability to the
macromolecules to some extent, and especially in discontinuous endothelia, larger fenestrations
may allow passage of lipid particles such as chylomicrons (75-600 nm) and cellular debris
(Levick and Smaje, 1987). Once these entities pass through the fenestra, they would be collected
by the nearby lymphatic vessels to the lymph nodes or circulating in the lymphatic system.
Thereby, DSE droplets could undergo this pathway and end up in the lymphatic system. Yet these
speculations require further investigation.
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4.4.3. The biodistribution of ME and LE
DME and DLE both resulted in substantially distinct concentration-time profiles in the various
tissues from DSE, but similar to each other with some differences. To further illustrate how DME
and DLE altered the biodistribution of DiI, the point-to-point comparison of the tissue
concentration ratio at each sampling time were utilized and the results are presented in Table 4.1.
The advantage of this approach was that it did not rely on any assumption, yet practically the
concentration in specific tissues is the determinant factor for the pharmacodynamic (PD) effect
for most of the drugs. Furthermore, statistical analysis could also be performed.
As shown in Table 4.1, the mean concentrations in the tissues by DME and DLE were first
compared statistically. Values presented with underscore indicate the significant differences at
95% confidence. Due to the large variations, many comparisons did not yield statistical
differences though the mean value suggested potential difference. The increase of sample size
could possibly address the issue. Herein though, the biodistribution pattern was analyzed by the
color coding. The mean tissue concentration ratios of DME:DLE were grouped by four regions. A
more than 2-fold in favor of DME was red-shaded, followed by the yellow area of favored DME
but within 2-fold, then the blue area of favored DLE within 2-fold and lastly the blank area of
favored DLE with more than 2-fold. The results demonstrated foremost that DME distributed in
various tissues universally higher than DLE at 0.5 h and from 6 h and on. This non-specific
enhanced tissue exposure should be due to the earlier peak at 0.5-1 h and the prolonged blood
circulation of DME. On one side, it could be a useful formulation to deliver lipophilic anticancer
drugs to the tumor by EPR; opposingly, as elaborated by Bittner, the change in PK by HS
especially its non-specific high organ dispositions could possibly increase the encapsulated drugs
toxicity (Bittner et al., 2003). This side effect could be elevated in certain tissues such as the heart
based on our observation. As suggested by the color coding, DME had a higher heart distribution
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compared to DLE almost throughout the test period. Secondly, DLE peaked at 2 h which caused a
higher concentration in all the tissues than DME though this peak rapidly decreased ever since.
Thirdly, the clear region of the liver, spleen and lungs from 0.25 to 2 h (except for 0.5 h) indicates
a favorable distribution into these tissues by DLE and such pattern could be extended to 4 h just
with less extent. As discussed previously, the vascular fenestration of the endothelia presented in
the liver and spleen serves as a passive “mesh” (Braet et al., 2007; Chen and Weiss, 1973).
Therefore, the larger droplet of DLE could be much easily trapped in these tissues whilst DME
alleviated such effect due to the closeness of size to the cutoff. The reticuloendothelial system
(RES) is also responsible for clearing particulate matters such as bacteria, fungi, viruses and
dying cells from the circulation (Aschoff, 1924). As the droplet size increases, chances are that
they could be more easily recognized thus subsequently end up mainly in the liver, spleen and
lungs which are the major constituents of RES.
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Table 4.1 The tissue mean concentration ratio of DME versus DLE
Time (h)
Tissue
0.25

0.5

1

2

4

6

10

Plasma

0.761

1.273

1.953

0.344

0.694

*19.884

11.926

Heart

1.611

6.352

2.927

0.599

2.096

34.259

29.989

Liver

0.159

2.639

0.335

0.206

0.674

27.214

12.647

Spleen

0.324

6.127

0.542

0.097

0.729

115.887

18.333

Lung

0.166

15.331

0.156

0.029

1.078

109.623

13.094

Kidney

0.747

3.226

1.493

0.195

0.693

8.357

11.177

Stomach

0.622

1.825

1.213

0.454

1.467

5.854

9.268

Intestine

12.528

1.990

1.095

0.427

2.192

4.901

8.681

Colon

1.000

0.830

1.257

0.364

1.095

3.436

4.216

Brain

1.126

0.697

0.772

0.296

0.701

2.224

1.881

Tumor

0.496

1.597

0.588

0.264

1.143

5.280

28.358

* Value presented with underscore indicates a significant difference at P < 0.05 (n=3).
DME/DLE: >2 (red), 1-2 (yellow), 0.5-1 (blue) and <0.5 (blank).
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4.5. Summary
DiI concentration-time profiles in various tissues were obtained after intravenous injection of DS,
DSE, DME and DLE. The characteristics of the biodistribution pattern of the studied NEs are
summarized in Table 4.2.
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Table 4.2 The characteristics of the studied NE biodistributions
Small-size NE
(~30 nm)

Medium-size NE
(~200 nm)

Large-size NE
(~900 nm)

Plasma
circulation

Not prolonged

Significantly prolonged

Not prolonged

Plasma
concentration

Low

High

Intermediate

Very low

Significantly enhanced,
more profound in a
long period of time

Highly enhanced in the
early hours, rapidly
cleared then

Preferably
distributed
organ

Not found

The RES organs and
the heart

The RES organs
especially the spleen
and the lungs

Subcutaneous
tumor
accumulation

Not significant

Highly enhanced

Intermediately
enhanced

RES organs
(Liver, spleen
and lungs)
accumulation
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Chapter 5. Conclusion and perspectives

In this chapter:
•

The current study is concluded and

•

Some perspectives originated from this study are provided.

5.1. Conclusion
In the current study, DiI loaded NEs with defined droplet sizes (~30, 200 and 900 nm) were
prepared and tested in vivo for their biodistributions in C57BL/6J mice. The biodistributions of
the NEs were impacted by their droplet size and surface PEG density. DSE did not show
significant exposure to the tissues of interest and the biological fate required further
investigations. DME showed a prolonged blood circulation, non-specific higher tissue
accumulation than the other size NEs especially in the heart and tumor. DLE demonstrated a
preferable accumulation in the liver, spleen and lung and subsequently quickly cleared from these
organs.

5.2. Perspectives
Our current study has explored the intravenous NEs in vivo biodistribution patterns in C57BL/6J
mice. The results suggest that the droplet size and surface PEG density contributed to the NEs
biological fate. It needs to be pointed out that the distinct tissue uptake by different formulations
should be carefully extrapolate to the other animal models or human. Species-dependent organ
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specificity for liposome was previously observed (Sou et al., 2011). The inter-species difference
is largely attributed to the significant different circulation time, and this effect is amplified
especially in the small rodents such as mice and rats as compared to hamster, rabbit and rhesus
monkey. Another important physiological difference between animal models is the balance
between organ/tissue to body weight ratio. Research has shown the spleen-to-body weight ratio of
the rat is 3 times greater than that of the primate and 9 times greater than the that of the rabbit.
This variation of mass balance of mononuclear phagocytic system (MPS) is therefore a crucial
factor determining the biodistribution of liposomes between rats and rabbits (Sou et al., 2005).
Despite that the species difference should be scrutinized, yet the current study intrigues several
potential follow-up research threads. First of all, it would be interesting to investigate the
biological fate of small-size NE. Should SE truly end up in the bone marrow and lymphatic
system, its containment in the circulatory system could be potentially useful in reducing systemic
especially hepatic and renal toxicity of anticancer drugs in the treatment of blood-originated
cancer such as leukemia and bone-related cancer. On the other hand, the favorable disposition of
LE in the liver, spleen and lungs could be utilized as a size-dependent passive targeting strategy.
Drugs which yield PD effect in these organs, such as Triclabendazole for fascioliasis and
antibiotics for pulmonary infections, etc., could be encapsulated in LE for liver and lung targeted
delivery, respectively. Secondly, for stage III liver and lung cancer, since the cancer has advanced
to the nearby lymph nodes, the liver/lung targeting effect by LE could be possible to treat the
whole organ and inhibit its distal metastasis. Further evaluation and comparison of the treatment
efficacy of anticancer drug loaded ME and LE for liver/lung locally invaded tumor is hence
desired to test the hypothesis. Notably, for these drug delivery purposes, LE should be optimized
in such a way that the droplet size be reduced with wider size distributions acceptable for the
improved formulation stability. Indeed, our preliminary results demonstrated that soybean lecithin
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was an excellent NE stabilizer which simultaneously produce mean droplet size ranging from 300
to 500 nm. In this regard, the commercialized intravenous lipid nutrition could possibly serve the
same purpose as the potential DDS for liver/lung targeted drug delivery. And lastly, the enhanced
heart distribution by ME could similarly open up certain research potential for heart targeted
delivery.
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Appendices
The PK parameters from the current study were summarized in appendices. The parameters were
obtained by non-compartmental analysis (NCA) with the aid of Phoenix® WinNonlin® (Certara,
NJ). Linear trapezoidal and linear interpolation method with a uniform weighting were used to
run the calculations. The PK parameters from DS, DSE, DME and DLE were summarized in
Table A.1 through Table A.4, respectively. Figure A.1 illustrates the extent of the change in
dose normalized DiI area under the curve (AUC0-10h) in various tissues by DSE, DME and DLE
versus DS, respectively. Table A.5 compares DME and DLE by the ratio of plasma-normalized
tissue AUC0-10h to show the intrinsic tissue affinity of the formulations.
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Table A.1 Major apparent PK parameters in tissues followed by intravenous bolus
administration of 5 mg/kg DiI in solution (DS) in C57BL/6J mice.
Cmax
(µg*mL-1

Tmax

MRT0-10h

MRT0-∞

AUC0-10h

AUC0-∞

µg*g-1*h)

(µg*mL-1*h or
µg*g-1*h)

3.34

7.45

8.30

2.55

4.16

2.27

2.59

0.5

3.97

10.87

23.28

38.40

32.68

0.5

3.77

8.45

35.92

51.05

Lung

15.52

0.25

3.17

4.18

14.49

15.93

Kidney

0.96

0.5

3.87

8.85

1.78

2.66

Stomach

0.30

0.5

4.75

8.47

1.62

2.31

Small Intestine

0.40

0.5

4.50

14.79

1.23

2.54

Colon

0.23

0.25

4.92

19.48

1.03

2.64

Tumor

0.39

0.5

4.79

19.22

1.12

2.81

or

µg*g-1)

(h)

(h)

(h)

Plasma

24.01

0.0

1.97

Heart

2.74

0.5

Liver

16.34

Spleen

90

(µg*mL-1*h

or

Table A.2 Major apparent PK parameters in tissues followed by intravenous bolus
administration of 2 mg/kg DiI in small-size nanoemulsion (DSE) in C57BL/6J mice.
Cmax

Tmax

MRT0-10h

MRT0-∞

AUC0-10h

AUC0-∞

(µg*mL-1 or
µg*g-1)

(h)

(h)

(h)

(µg*mL-1*h or
µg*g-1*h)

(µg*mL-1*h or
µg*g-1*h)

Plasma

19.23

0.0

2.32

15.57

5.80

10.66

Heart

0.74

0.25

4.28

45.01

1.52

7.14

Liver

1.44

0.25

5.43

N/A*

11.18

N/A

Spleen

1.13

0.25

5.41

N/A

5.99

N/A

Lung

0.48

0.25

4.76

68.59

1.56

11.38

Kidney

0.33

0.25

4.79

49.26

1.59

8.51

Stomach

0.25

4.0

5.50

N/A

1.86

N/A

Small Intestine

0.22

0.25

5.01

39.04

1.37

6.27

Colon

0.21

10.0

6.00

N/A

1.17

N/A

Brain

0.08

0.25

5.02

67.36

0.59

4.38

Tumor

0.16

0.25

5.46

N/A

1.01

N/A

*N/A: Not available.

91

Table A.3 Major apparent PK parameters in tissues followed by intravenous bolus
administration of 5 mg/kg DiI in medium-size nanoemulsion (DME) in C57BL/6J
mice.
Cmax

Tmax

MRT0-10h

MRT0-∞

AUC0-10h

AUC0-∞

(µg*mL-1 or
µg*g-1)

(h)

(h)

(h)

(µg*mL-1*h or
µg*g-1*h)

(µg*mL-1*h or
µg*g-1*h)

Plasma

29.19

0.0

3.92

9.01

79.69

120.25

Heart

10.01

1.0

4.76

32.57

50.33

192.91

Liver

20.65

10.0

5.97

N/A*

146.67

N/A

Spleen

31.03

4.0

5.58

N/A

198.67

N/A

Lung

37.39

0.5

4.58

5.19

128.58

138.80

Kidney

3.83

0.5

4.84

17.92

14.92

35.97

Stomach

2.35

0.5

5.31

69.78

10.34

82.98

Small Intestine

2.20

0.5

5.37

N/A

8.77

N/A

Colon

0.81

0.5

5.43

N/A

4.14

N/A

Brain

0.46

0.5

4.37

10.49

1.37

2.24

Tumor

3.01

10.0

7.01

N/A

11.88

N/A

*N/A: Not available.
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Table A.4 Major apparent PK parameters in tissues followed by intravenous bolus
administration of 5 mg/kg DiI in large-size nanoemulsion (DLE) in C57BL/6J mice.
Cmax

Tmax

MRT0-10h

MRT0-∞

AUC0-10h

AUC0-∞

(µg*mL-1 or
µg*g-1)

(h)

(h)

(h)

(µg*mL-1*h or
µg*g-1*h)

(µg*mL-1*h or
µg*g-1*h)

Plasma

39.43

0.0

2.11

2.21

66.76

67.39

Heart

5.63

2.0

2.55

2.65

18.10

18.29

Liver

28.91

2.0

2.96

3.09

126.65

128.50

Spleen

69.44

2.0

2.73

2.76

220.79

221.46

Lung

41.53

2.0

2.48

2.48

140.41

140.55

Kidney

4.85

2.0

2.71

2.83

14.57

14.76

Stomach

1.50

2.0

2.90

3.47

5.88

6.22

Small Intestine

1.11

0.5

3.12

4.19

4.09

4.52

Colon

0.97

0.5

3.34

4.97

2.81

3.28

Brain

0.66

0.5

3.00

4.00

1.60

1.76

Tumor

2.27

2.0

2.80

3.07

6.62

6.81

93

25
DSE
DME
20

DLE

Fold

15

10

5

0

Figure A.1 The comparison of dose normalized DiI apparent area under the curve
(AUC0-10h) in various tissues after intravenous bolus injection of DiI loaded small-,
medium- and large-size nanoemulsion (DSE, DME and DLE) versus DiI solution (DS),
respectively.
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Table A.5 The ratio of plasma-normalized tissue apparent AUC0-10h by DME versus
DLE
Plasma normalized AUC0-10h
DME

DLE

Normalized
ratio

Plasma

N/A*

N/A

N/A

Heart

0.653

0.293

2.23

Liver

1.902

2.048

0.93

Spleen

2.493

3.307

0.75

Lung

1.667

2.271

0.73

Kidney

0.193

0.236

0.82

Stomach

0.134

0.095

1.41

Intestine

0.114

0.066

1.73

Colon

0.054

0.045

1.20

Brain

0.018

0.026

0.69

Tumor

0.154

0.107

1.44

Tissue

* N/A: Not applicable.
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